Review



cox proportional hazards model  (TriNetX Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    TriNetX Inc cox proportional hazards model
    Cox Proportional Hazards Model, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards model/product/TriNetX Inc
    Average 90 stars, based on 1 article reviews
    cox proportional hazards model - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    cox proportional hazards model  (TriNetX Inc)
    90
    TriNetX Inc cox proportional hazards model
    Cox Proportional Hazards Model, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards model/product/TriNetX Inc
    Average 90 stars, based on 1 article reviews
    cox proportional hazards model - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazards model  (MathWorks Inc)
    90
    MathWorks Inc cox proportional hazards model
    Cox Proportional Hazards Model, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards model/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    cox proportional hazards model - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)  (STATA Corporation)
    90
    STATA Corporation cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazards Modeling With Stabilized Inverse Probability Of Treatment Weighting (Iptw), supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)/product/STATA Corporation
    Average 90 stars, based on 1 article reviews
    cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw) - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazard models  (TriNetX Inc)
    90
    TriNetX Inc cox proportional hazard models
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazard Models, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazard models/product/TriNetX Inc
    Average 90 stars, based on 1 article reviews
    cox proportional hazard models - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazard models  (SAS institute)
    90
    SAS institute cox proportional hazard models
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazard Models, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazard models/product/SAS institute
    Average 90 stars, based on 1 article reviews
    cox proportional hazard models - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    kaplan-meier and cox proportional hazards models  (TriNetX Inc)
    90
    TriNetX Inc kaplan-meier and cox proportional hazards models
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Kaplan Meier And Cox Proportional Hazards Models, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kaplan-meier and cox proportional hazards models/product/TriNetX Inc
    Average 90 stars, based on 1 article reviews
    kaplan-meier and cox proportional hazards models - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    power calculation platform for proportional hazards regression (cox model)  (STATA Corporation)
    90
    STATA Corporation power calculation platform for proportional hazards regression (cox model)
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Power Calculation Platform For Proportional Hazards Regression (Cox Model), supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/power calculation platform for proportional hazards regression (cox model)/product/STATA Corporation
    Average 90 stars, based on 1 article reviews
    power calculation platform for proportional hazards regression (cox model) - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazards regression models v15.1  (STATA Corporation)
    90
    STATA Corporation cox proportional hazards regression models v15.1
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazards Regression Models V15.1, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards regression models v15.1/product/STATA Corporation
    Average 90 stars, based on 1 article reviews
    cox proportional hazards regression models v15.1 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cox proportional hazards model  (Meira Corporation)
    90
    Meira Corporation cox proportional hazards model
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazards Model, supplied by Meira Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox proportional hazards model/product/Meira Corporation
    Average 90 stars, based on 1 article reviews
    cox proportional hazards model - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

    Journal: JAMA Network Open

    Article Title: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

    doi: 10.1001/jamanetworkopen.2025.15087

    Figure Lengend Snippet: Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

    Article Snippet: After MICE, we used Cox proportional hazards modeling with stabilized inverse probability of treatment weighting (IPTW) to assess the adjusted association of anti-EGFR vs anti-VEGF–containing treatment with OS using Stata/SE statistical software version 18.5 (StataCorp) (eMethods, eFigure 1, and eFigure 2 in ).

    Techniques: Generated